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medical resource use, impact on productivity for both patients and carers, and
detrimental effects on education and careers.
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OBJECTIVES: Idiopathic Pulmonary Fibrosis (IPF) is a rare, irreversible and eventu-
ally fatal fibrosing lung disease. Cough and dyspnea are major symptoms. The
study objective was to assess the content validity of the Cough and Sputum As-
sessment Questionnaire (CASA-Q) cough domains and the UCSD Shortness of
Breath Questionnaire (SOBQ), instruments developed for use in chronic obstructive
pulmonary disease, when used in patients with IPF. METHODS: Cross-sectional,
qualitative study with cognitive interviews in patients with IPF. Study outcomes
included relevance, comprehension of item meaning, understanding of the in-
structions, recall period, response options, and concept saturation. RESULTS: In-
terviews were conducted with 18 patients. The mean age was 68.9 years (SD 11.9),
78% were male and 89% were Caucasian. The mean time since IPF diagnosis was 2.4
years (SD 1.6). Most participants (89%) found the CASA-Q cough domain items to be
highly relevant to their condition. The intended meaning of the items was clearly
understood by most of the participants (89-100%). All participants understood the
CASA-Q instructions; the correct recall period was reported by 89% of the patients,
and the response options were understood by 76%. Most participants (83%) re-
ported positive feedback for the SOBQ; those who did not were symptom free and
hence had no limitation in activities to report. The intended meanings of the items
were relevant and clearly understood by all participants. Participants understood
the instructions (83%) and all patients understood the response options. The recall
period produced varying responses, based on the type of activity performed. No
concepts were missing, suggesting that saturation was demonstrated for both
measures. CONCLUSIONS: Content validity and saturation for the CASA-Q cough
domain and SOBQ was established with items perceived as relevant to measure
symptoms of IPF. The results of this study support the use of these instruments in
IPF clinical trials.
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OBJECTIVES: To evaluate disease-specific quality of life (QoL) in children with
asthma according to patients’ and their parents’ perspective. METHODS: Hungar-
ian version of the Standardised Paediatric Asthma Quality of Life Questionnaire
(PAQLQ(s)) and the Paediatric Asthma Caregiver’s Quality of Life Questionnaire (PACQLQ)
were completed. The minimal important difference in the PAQLQ total score is 0.5
on the 7-point Likert scale, higher scores indicate better QoL. Asthma control was
assessed by Asthma Control Questionnaire (ACQ); Forced Expiratory Volume in 1 sec-
ond (FEV1) was measured via spirometry. RESULTS: A total of 125 children (7-17
years of age) and their caregivers completed the questionnaires. Overall PAQLQ
score was 5.740.97, overall PACQLQ score was 5.321.22 (r0.83), mean ACQ score
was 1.650.8 and mean FEV1 was 100.7114.91. PACQLQ scores were statistically
(p0.001) and clinically significantly lower, than PAQLQ scores. Correlations be-
tween FEV1 and overall score of PAQLQ(s) (r-0.15) and overall PACQLQ score (r-
0.005) were weak and not significant. The association between ACQ and total score
of PAQLQ(s)(r-0.64, p0.01) was moderate. CONCLUSIONS: Our participants had
poor asthma control despite their good lung function. Weak relationship was found
between spirometry and QoL according to patients’ and caregivers’ opinion; how-
ever QoL correlated only moderately with the level of asthma control. PAQLQ is able
to detect small but clinically important changes that children experience as a result
of the treatment or as a part of the natural fluctuation of their asthma, it provides
additional valuable information for clinical practice; children aged over 7 can pro-
vide reliable data on their Qol, where as parents often do not rate their children’s
Qol appropriately.
PRS38
TURKISH CULTURAL ADAPTATION AND VALIDATION OF SMOKING CESSATION
QUALITY OF LIFE (SCQOL) QUESTIONNAIRE
Oksuz E1, Malhan S2, Baytar S1, Yilmaz F1
1Baskent University, Ankara, Turkey, 2Baskent University, Anakara, Turkey
OBJECTIVES: The Smoking Cessation Quality of Life (SCQoL) questionnaire as-
sesses the change in well-being and functioning associated with smoking cessa-
tion. The SCQoL includes 14 questions. This study aims to adapt the SCQoL into
Turkish language and culture and, check the reliability and validity of the inven-
tory culturally. METHODS: The original instrument was forward then back-trans-
lated by two independent translators. A small sample consisting of 42 people was
used to check the initial comprehension and convenance. Cronbach’s Alpha was
used to assess reliability and factor analysis to assess dimensionality. The Euro-
Qol-5D questionnaire and corresponding Visual Analogue Scales were used for
concurrent validity.RESULTS:A total of 152 people participated in this study. 55.9%
of them were female, 44.1% of them being male. Mean age was 24.3. The internal
consistency coefficient (Cronbach’s alpha) of SCQoL was 0.771. Factor analysis of
the scale revealed that it was composed of four factors and accounting for 67% of
the total variance. Correlations were moderate with EuroQol and VAS.
CONCLUSIONS: The culturally adapted to Turkish SCQoL has good validity and
reliability, making it a potentially useful outcome measure in determining the
effect of quality of life of people in Turkey.
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OBJECTIVES: Pulmonary arterial hypertension (PAH) is a chronic, debilitating dis-
ease characterized by an increase in blood pressure in the pulmonary arteries and
is associated with a burdensome low tolerance to exercise. Treprostinil is indicated
in the treatment of PAH in patients with New York Heart Association Class II-IV
symptoms and is available in one of two forms: infused or inhaled. The present
study determined the preference among members of the general public for one
treatment delivery option over the other, as well as the willingness-to-pay (WTP)
for the inhaled option. METHODS: An online survey of members of the general
public, 18 years of age or older, in the province Ontario, Canada, was conducted by
presenting descriptive and clinical information on each treatment delivery option,
ascertaining the participants’ preference for one option over the other, and, by
inviting participants who opted for the inhaled form to take part in a bidding game
evaluating their WTP in terms of additional monthly insurance premiums to en-
sure that inhaled treprostinil would be covered by a hypothetical insurance
scheme. Descriptive statistics and sub-group analyses based on demographic char-
acteristics were calculated with regards to preference and WTP. RESULTS: The
recruited population was more likely to be female, younger and with a higher
yearly household income, when compared to the population of Ontario. Of the 386
survey participants, 85.8% preferred the inhaled treatment option, with no signif-
icant differences in terms of preference observed across age or gender. The ob-
served median (minimum, maximum, mode) and mean (95% confidence interval)
WTP in monthly insurance premiums were CAD21.50 (CAD0, CAD200, CAD50) and
CAD37.25 (CAD32.51, CAD41.99), respectively; sub-group analyses based on gender,
age or yearly household income yielded no significant differences. CONCLUSIONS:
Inhaled treprostinil appears to be preferred over infused treprostinil and is associ-
ated with relatively high WTP for insurance premiums.
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OBJECTIVES: Pharmaceutical companies are increasingly shifting from a product-
centered to a customer and service-centered culture and many companies have
developed disease management programs for illnesses like asthma, COPD, diabe-
tes, arthritis, depression etc. Such programs come in all shapes and sizes and their
main aim is to improve the quality of care are reduce hospital costs. However, there
is insufficient evidence of cost-effectiveness of disease management programs.
Aim: The aim of this study is to review the impact of COPD disease management
(COPD-DM) programs on health care costs and outcomes. We also investigated the
impact of disease-, intervention-, and study-characteristics. METHODS: We con-
ducted a systematic review of cost-effectiveness studies of COPD-DM. The results
were grouped by study, intervention and disease characteristics and, where feasi-
ble, included in a random-effects meta-analysis. RESULTS: We included 16 papers
describing 11 studies. The meta-analysis showed that COPD-DM decreased the RR
of hospitalizations (RR: 0.71 [95CI: 0.53-0.96]), and led to a reduction of hospitaliza-
tion costs (€1093 [95CI: €2052-€133]) and average health care savings were €922
[95CI: €1549-€295] per patient. These savings have to be weighed against the costs
of developing, implementing and managing the DM program. There was substan-
tial heterogeneity. DM showed greater savings in hospital costs in studies including
severe COPD patients (GOLD stage 3). Savings were also greater when COPD-DM
programs addressed 3 or more components of the Chronic Care Model and in
studies from non-EU origin. CONCLUSIONS: DM decreased the risk of hospitaliza-
tion and health care costs (excluding program costs), but results varied by study-,
intervention-, and disease-characteristics. Future studies should more explicitly
include the overhead costs of running these DM programs.
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OBJECTIVES: Respiratory Syncytial virus (RSV) is the leading cause of respiratory
tract infections. Efficacy of Palivizumab in reducing RSV related hospitalizations
has been proven in preterm born infants and children with congenital heart dis-
ease (CHD) or bronchopulmonary dysplasia (BPD). However, the high costs of
Palivizumab may limit its use. This study described the characteristics of Palivi-
zumab users in the Netherlands and assessed the determinants of receiving Palivi-
zumab among infants with an indication according to the label. METHODS: Data
for this study were obtained by linking the PHARMO database network, which
includes detailed information on drug dispensing and hospitalization histories,
and The Netherlands Perinatal Registry, including perinatal medical case records.
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From this linked cohort, all infants born between April 1, 1999 and March 31, 2007
were selected and characteristics of those receiving Palivizumab were described.
Among infants with an indication to receive Palivizumab (i.e. born35 weeks, CHD
or BPD), recipients were compared with non-recipients and determinants of receiv-
ing Palivizumab were examined using logistic regression analyses. RESULTS:
Among the 3321 infants with an indication to receive Palivizumab, only 15% were
recipients. The majority was born32 weeks of gestation and mean age at first use
was 3.1 months. The strongest predictor of receiving Palivizumab was being born
32 weeks (OR 49.1; 95%CI 31.5-76.4). However, among the infants born32 weeks,
still 50% did not receive Palivuzmab. Subanalyses among this group showed that
the likelihood of receiving Palivizumab was higher for infants born in later years,
having respiratory distress syndrome or being hospitalized in the RSV season.
CONCLUSIONS: In the Netherlands, Palivizumab is mostly prescribed to infants
born32 weeks, which is according to Dutch guidelines. Use has increased over the
years. However, not all children addressed in the label indication are receiving
Palivizumab.
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OBJECTIVES: Information on the implementation of national (NVL) and interna-
tional guidelines (GINA and GOLD) for asthma and COPD in German clinical prac-
tice is limited. METHODS: Research on inhaled corticosteroid/long-acting 2-ago-
nists (ICS/LABA) in asthma and COPD in Germany was conducted by a modified
Delphi Process with a panel of physicians (six GPs and four pulmonologists) to
produce 25 consensus statements. RESULTS: Three consensus statements provide
insight into current controversies on ICS/LABA use in German clinical practice.
Consensus on the statement “Early initiation onto ICS/LABA therapy can improve
asthma control and help reduce the rate of exacerbations for patients with persis-
tent asthma who are not sufficiently controlled”, suggests that this is current clin-
ical practice in Germany, consistent with GINA, rather than with the NVL recom-
mendation of doubling the ICS dose. The panel agreed that stepping down LABA in
established ICS/LABA therapy, would lead to loss of control and/or worsening of
symptoms in around 50% of patients. It was agreed that by early initiation of ICS/
LABA in uncontrolled asthma 70–80% of health care resource utilisation could be
avoided. Another statement: “A typical patient that should be initiated on ICS/
LABA has moderate to severe COPD, suffers from symptoms and experiences ex-
acerbations” suggests that clinical practice among German physicians anticipated
the 2011 GOLD guideline, in which initiation of a fixed ICS/LABA combination is
based on combined assessment of COPD severity including exacerbation history
and the presence of symptoms. The panel estimated that timely initiation of ICS/
LABA therapy in COPD patients could prevent 10–40% of unscheduled visits (hos-
pitalisations, emergency room and physician visits). CONCLUSIONS: The results of
this research suggest that early initiation of ICS/LABA therapy could substantially
reduce unscheduled treatment costs in asthma patients, and that timely introduc-
tion of LABA/ICS therapy for COPD patients could substantially reduce both un-
scheduled treatment and hospitalisation costs.
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OBJECTIVES: Chronic Obstructive Pulmonary Disease (COPD) is a major public
health problem. It is often under-diagnosed and undertreated. Prevalence of COPD
is strongly correlated with smoking habits but it affects non-smokers (including ex-
and passive smokers) also. Early and effective treatment can reduce health care
resource use by decreasing the severity and number of exacerbations. Indacaterol
is an “ultra”-long-acting 2-agonist indicated for long-term maintenance broncho-
dilator treatment of airflow obstruction in patients with COPD. METHODS: We
estimated the prevalence of COPD, and the incidence of exacerbations in a single
hospital district with 200,000 inhabitants (Etelä-Pohjanmaa) in one year. Popula-
tion-based data and smoking habits were utilized. Published indacaterol data were
used to estimate the incidence and severity of exacerbations w/wo medication.
Health care resource use was included from both primary and secondary health
care. RESULTS:The estimated number of COPD patients in the hospital district was
13,700 (prevalence 6.85%, out of which 49% were currently non-smokers and 42% in
working age). The patient population potentially benefiting from treatment (GOLD
stages I-IV), was estimated to be 12,000 (87.6% of all COPD-patients). Within one
year, without medication the number of expected exacerbations was 8,634, 3% of
them were severe (needing hospitalization). Applying data from published inda-
caterol trial, 31% of exacerbations could be avoided by medical treatment. This can
lead to a reduction of inpatient days by 800, and outpatient visits by 2,555 among
this patient population in this hospital district. CONCLUSIONS: Based on the
model, in this hospital district, COPD affects almost 7% of the population. In addi-
tion to elderly heavy smokers, health care workers should be aware of the large
working age non-smoking population with possibility of having COPD. Early detec-
tion and effective treatment of COPD may decrease the number of exacerbations
and consequently reduce the use of health care resources.
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OBJECTIVES: To assess continuity of care and to examine any association between
continuity of care and health outcomes (hospitalization, emergency department
visits, deaths and medical costs in Korea. METHODS: This was a retrospective
cohort study using the Korea National Health Insurance Claim Database. Patients,
40 years of age, who were diagnosed with COPD in 2007 (n49,635) were moni-
tored for four years, until 2010. RESULTS: As continuity of care increased, the risks
of hospitalization, emergency department visits, and deaths decreased, as did
medical costs. Also, variables that had significant affects on continuity level for
COPD patients were gender, age, experience of hospitalization, frequency of am-
bulatory visits, number of institution visited, the type of the main clinics attended,
and Charlson’s score. The correlation analysis regarding continuity levels and odds
ratios of health outcomes for COPD patients produced the following results. In
comparison between the first quartile group and the fourth quartile group of COC,
the fourth quartile group had higher rate of hospitalization by 1.61 (95% CI: 1.51-
1.72), a higher emergency department usage by 1.53 (95% CI: 1.41-1.67), and an
increased death rate by 1.26 (95% CI: 1.02-1.56). The odds of fourth quartile belong-
ing to the high costing group were also higher than first quartile (OR1.54, 95% CI:
1.44-1.64). The associations of COC with health outcomes and costs were stronger
when analysing patients visiting a primary institution, as their main attending
medical institution. CONCLUSIONS: As a result, it is proven that improving the
continuity level reduces the risk of hospitalization, ER visits, deaths and medical
costs in COPD patients. Therefore, policy makers needs to develop and actively
move forward the program to improve the continuity level of care in patients with
COPD, especially for the patients using the primary health care service.
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OBJECTIVES: To assess continuity of care and to examine any association between
continuity of care and health outcomes (hospitalization, emergency department
visits), also effects on medical costs. METHODS: This was retrospective cohort
study using the Korea National Health Insurance Claim Database. Patients, 40
years of age, who were first diagnosed with COPD in 2008 (n34,249) were moni-
tored for the following 2 years at specific index dates. RESULTS: The mean of the
COC was 0.91970.1859 retrospectively. As the continuity of care increased, the
risks of hospitalization and emergency department visits decreased, along with
medical costs. Also, variables that have significant affects on continuity level for
COPD patients were gender, age, experience of hospitalization, frequency of am-
bulatory visits, number of institution visited, type of the main attended clinic, the
first attending medical institution, and Charlson’s score. The correlation analysis
on the continuity levels, and hazard ratios of health outcomes showed the follow-
ing results. Comparing the continuity group by COC, the non-continuity group had
higher rate of hospitalization by 1.70 (95% CI: 1.54-1.87) and an increased emer-
gency department usage by 1.70 (95% CI: 1.46-1.99). The risk of non-continuity
group belonging to the high costing group were also higher than the continuity
group (OR1.54, 95% CI: 1.44-1.64). The associations of COC, with health outcomes
and costs, were stronger when analysing patients visiting primary institution as
opposed to attending main medical institutions. CONCLUSIONS: As a result, it is
proven that to improve continuity level, one needs to reduce the risk of deterio-
rated condition and medical costs in COPD patients. Therefore, the policy makers
need to develop and try actively to alter the program to improve the continuity
level of care in patients with COPD, especially for the patients using primary health
care service.
PRS46
HEALTH CARE RESOURCE USE OF PATIENTS WITH CYSTIC FIBROSIS (CF) IN
THE UK
Lambrelli D1, Wasiak R1, Ingram A2, Harrow B3, Becker C3, Eriksson D1, Wyatt H4
1United BioSource Corporation, London, UK, 2Xcelerate Health Outcomes, London, UK, 3Vertex
Pharmaceuticals Incorporated, Cambridge, MA, USA, 4King’s College Hospital, London, UK
OBJECTIVES: To document real world management and resource use for patients
with CF. METHODS: Retrospective, medical chart review in eight CF centres in UK.
A stratified random sample of charts was selected from the cohort of patients 6
years of age with a diagnosis of CF caused by genotypes G551D or DF508 homozy-
gous. The study period covered the most recent two years of complete data. Patient
and clinical characteristics, health care resource and drug usage were extracted.
Categorical variables were described as number and proportion of patients and
continuous variables were summarised using descriptive statistics. RESULTS:Data
for 200 patients (50% female, mean age 19.5) were reviewed, with N63 (32%) hav-
ing G551D genotype. Severity distribution measured using FEV1% was: 40%27,
40% and 70%69 and 70%96 patients respectively. Twenty different health
care professional types provided care. Nearly all patients (N199) had a clinic visit
(mean15.2 per patient, SD9.1, median13), and 23% (N45) having an emer-
gency visit (mean2.4 per patient, SD2.2, median2). For drug usage, IV antibi-
otics (73.5%, N147), nebulised therapy (87.0%, N174), and mucolytic treatment
(74.5%, N149) were frequently used. Pancreatic enzyme treatment was used by
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